Eli Lilly and Company $LLY Stock Holdings Cut by Glenview Trust Co

Glenview Trust Co lessened its stake in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 188,371 shares of the company’s stock after selling 1,448 shares during the quarter. Eli Lilly and Company makes up about 2.7% of Glenview Trust Co’s portfolio, making the stock its 6th biggest holding. Glenview Trust Co’s holdings in Eli Lilly and Company were worth $173,258,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. M.E. Allison & CO. Inc. increased its stake in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after purchasing an additional 10 shares in the last quarter. Tanager Wealth Management LLP raised its position in shares of Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC lifted its stake in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after buying an additional 10 shares in the last quarter. Wealthspan Partners LLC boosted its holdings in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after buying an additional 10 shares during the last quarter. Finally, G&S Capital LLC boosted its holdings in Eli Lilly and Company by 2.0% in the 4th quarter. G&S Capital LLC now owns 501 shares of the company’s stock worth $538,000 after buying an additional 10 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Eli Lilly and Company Trading Down 2.7%

Shares of Eli Lilly and Company stock opened at $1,146.90 on Tuesday. The stock has a market cap of $1.08 trillion, a P/E ratio of 40.74, a P/E/G ratio of 1.48 and a beta of 0.51. The stock’s 50 day simple moving average is $1,122.49 and its 200-day simple moving average is $1,036.98. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the business earned $3.34 earnings per share. The business’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 34.55 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LLY shares. Barclays increased their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Truist Financial boosted their price target on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.